SCHEMBL30889447

SCHEMBL30889447

NS(=O)(=O)c1cccc2[nH]c(C(=O)O)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 4/20 0.51
GPR35 Q9HC97 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
GRIN1 Q05586 2/20 0.51
MEN1 O00255 1/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
CYP1A2 P05177 1/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
MAPK1 P28482 1/20 0.51
CYP2C19 P33261 1/20 0.51
AHR P35869 1/20 0.51
CHRNA7 P36544 1/20 0.51
KMT2A Q03164 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24190029 0.84 KDM4E (0.51) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL22647495 0.83 KDM4E (0.53) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL2003980 0.82 KDM4E (0.53) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL30310312 0.78 KDM4E (0.59) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL2762336 0.78 KDM4E (0.59) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL145350 0.77 FLT3 (0.58) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL30097060 0.77 FLT3 (0.58) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL27518065 0.77 KDM4E (0.57) KDM4EHSD17B10GPR35ALDH1A1HPGD
SCHEMBL17034691 0.76 CYP1A2 (0.47) KDM4EHSD17B10ALDH1A1HPGDMEN1
SCHEMBL2806087 0.75 KDM4E (0.59) KDM4EHSD17B10GPR35ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024107778-A1 NOVEL PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-23 WO disclosed